Skip to main content
Glama

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

TDQS

A4.3/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

The annotations already mark the tool read-only, idempotent, open-world, and non-destructive, and there is no contradiction in the description. Beyond that, the description discloses substantive runtime behavior: internal cascading through multiple lookup endpoints, graceful degradation when GLEIF/OpenFIGI are unavailable, explicit `unresolved` output rather than omission, and source labeling of every identifier.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The definition is long, but almost every sentence earns its place by conveying examples, fallback behavior, or input formatting rules. It is front-loaded with natural-language examples and the 'Use FIRST' directive. A small deduction is fair because the content runs together in one dense paragraph rather than being broken into scannable bullets or sections.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with no output schema that consults multiple external sources, the description covers input formats, identifier sources, ambiguity handling, unresolved results, and failure degradation. An agent has enough decision-relevant context to select and invoke the tool correctly without further digging into external documentation.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100% and both `type` and `value` already have descriptions, so a baseline of 3 is appropriate. The description adds real value by detailing value formatting for bonds ('ISSUER exactly as printed', never the full noun phrase), accepting ISINs for company lookup, and explaining type-specific outputs such as RxCUI, FIGI, and LEI.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose4/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description centers on a specific action: resolving a user-spoken name to canonical/official identifiers, with two explicit supported entity types (company, drug) and concrete examples such as ticker, CIK, LEI, and RxCUI. It is not a tautology and clearly carves out a niche distinct from generic search, though it does not explicitly name or contrast sibling tools like `resolve` or `entity_profile`.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It contains an explicit directive: 'Use FIRST whenever you have a name but need an ID,' which is strong when-to-use guidance. It also sets expectations for ambiguity via `figi_candidates` and for graceful degradation when enrichment sources are unavailable. However, it does not name alternative tools or state when not to use this tool, such as when an identifier is already known and entity details are needed.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.5/5.0
Disambiguation2/5

Severe overlap exists between ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded, and deep_research, all of which route to the same 5,743-tool catalog with only subtle differences. The pair resolve (CURIE-to-URL) and resolve_entity (name-to-ID) share the same verb but mean completely different things in different domains, and the five polymarket tools have heavily overlapping purposes.

Naming Consistency2/5

The set mixes multiple conventions: noun-only names (prefix, prefixes, search, resolve), verb_noun names (generate_llms_txt, scan_dependency, validate_claim), adjective_noun names (recent_alerts, recent_changes), and vendor-prefixed names (ask_pipeworx*, pipeworx_*, polymarket_*). Some names break the pattern entirely, like forget and remember, and the plural prefix/prefixes pair is inconsistent.

Tool Count2/5

35 tools is heavy for any single server, but the bigger problem is that roughly 31 tools are Pipeworx platform utilities (asking, memory, subscriptions, feedback) while only 4 serve the stated 'Bioregistry' purpose. A server named Bioregistry carrying prediction-market arbitrage and AI-visibility tools is poorly scoped regardless of the absolute count.

Completeness2/5

The Bioregistry surface is thin: search, prefix, prefixes, and resolve cover lookup/pagination but no registry management, and the remaining tools belong to an entirely different, unrelated domain. The server's apparent purpose ('Bioregistry') is barely served, while the Pipeworx functionality, though broad, is buried under an incongruent server name, making the overall surface incomplete and incoherent.